An interventional study of CGM-Augmented FIM and FIM only in Nutrition, Type 2 Diabetes and T2DM, sponsored by University of North Carolina, Chapel Hill. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 2 by University of North Carolina, Chapel Hill — 1 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of North Carolina, Chapel Hill.
Among the 15 studies in Diabetes Mellitus, Type 2 by University of North Carolina, Chapel Hill, this one is the 10th largest by planned enrollment, is one of 4 that started in 2025, is one of 13 with no phase, and was the 14th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 15 studies in Diabetes Mellitus, Type 2 by University of North Carolina, Chapel Hill is open now, in 1 country. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 87 across the 15 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by University of North Carolina, Chapel Hill that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07148713University of North Carolina, Chapel HillPilot of Continuous Glucose Monitor-Augmented Food Is Medicine | 2026-12 |
| NCT05741125University of North Carolina, Chapel HillImproving Appetite Self-Regulation in African American Adults With Type 2 Diabetes | 2027-02-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 2 by University of North Carolina, Chapel Hill, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity. This study will learn if a FIM intervention ("intervention") that includes access to real-time CGM and nutrition counseling can increase engagement, improve glycemic management, and support healthy eating in this population, compared to the FIM intervention alone ("comparator").
At the study baseline, participants will be randomized to either the intervention or the comparator arm for 16 weeks. The intervention will occur during the first 12 weeks (phase 1: intervention phase) and will be compared to a standard FIM approach without CGM or counseling. Phase 2 (extension phase) will last 4 weeks and will consist of all participants in the intervention and comparator arm receiving both FIM and CGM for self-directed use. The study will also explore participant experiences through a series of semi-structured interviews with a subset of randomly selected participants to identify opportunities for scaling the intervention to a broader population.
This study is designed to test the feasibility and preliminary efficacy of a CGM-augmented FIM intervention for adults with type 2 diabetes and nutrition or food insecurity. The study will enroll adults with type 2 diabetes not using insulin/secretagogues or CGM to be randomized 1:1 to the CGM-augmented FIM intervention (intervention arm) or a standard FIM intervention (comparator arm) for 12 weeks. All participants (N=60) will wear blinded CGM for 10 to 14-days at baseline and at week 12, and complete two random 24-hour dietary recalls during each blinded CGM wear-time. Participants in the intervention arm will wear real-time CGM for the duration of the 12-week intervention and receive a series of structured counseling sessions with a registered dietician. Following the 12-week intervention, all participants will receive both FIM intervention and wear real-time CGM for a 4-week extension phase. FIM intervention will be provided in the form of electronic healthy food vouchers.
At the 12-week and 16-week timepoints, participants will provide outcome data including blinded CGM data, hemoglobin A1c, dietary intake, and other patient-reported outcomes and feedback on their experience using questionnaires. After study completion, a subset of sampled participants will be invited to complete a semi-structured interview regarding their experience with the study. Participants in the intervention group will be invited after the completion of the intervention (beginning week 13) and participants in the comparator group will be invited to interview after completion of the entire study (beginning week 17). The primary outcomes measuring study feasibility and acceptability will collect data related to CGM and FIM use, including overall retention and phase completion, CGM wear-time, use of food subsidy, completion of meal logs, and satisfaction for the intervention. The primary outcomes measuring efficacy will collect diabetes outcomes, glycemic management, and a suite of patient-reported outcomes. Quantitative and qualitative results will be used to improve the intervention prior to rollout of a subsequent multicenter, fully powered randomized trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 diabetes as defined by self-report and confirmed by ICD-10 codes
Indication of a barrier to healthy eating consisting of report of food insecurity (defined as a score greater or equal to 1.0 on the 6-item USDA Food Security Survey Module (FSSM)) and/OR nutrition insecurity (defined as more often than 'Rarely' on the One-Item Gretchen Swanson Nutrition Screener, OR more often than 'Not Very Hard' on the Two-item Nutrition Security Screener (NSS))
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CGM-Augmented FIM
Behavioral: CGM-Augmented FIM
FIM only
Behavioral: FIM only
The intervention arm will receive electronic healthy foods vouchers and unblinded, real-time CGM sensors for 16-weeks, in addition to individualized nutrition counseling with a registered dietician for 5-8 sessions (all participants will attend 5 sessions, with up to three additional sessions scheduled as needed based a set of a-priori decision rules).
The comparator arm will receive electronic healthy foods vouchers and healthy eating resources and self-directed nutrition education. This group will not receive unblinded CGM sensors or any nutrition counseling for the first 12 weeks. This group will receive 30-days of unblinded CGM sensors to use in the extension phase only.
Change in percent of Time in Range (TIR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values between 70-180 mg/dL will be measured using 7-14 days of retrospective data at each time-point. Change in TIR will be calculated across time-points.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in percent of Time Below Range (TBR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hypoglycemic range (\<70 mg/dL) will be measured using 7-14 days of retrospective data at each time-point. Change in TBR will be calculated across time-points.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in percent of Time Above Range (TAR)
When using the blinded continuous glucose monitors (CGM), the percentage of sensor values in the hyperglycemia range (\>180 mg/dL) will be measured using 7-14 days of retrospective data at each time-point. Change in TAR will be calculated across time-points.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Glycemic variability
When using the blinded continuous glucose monitors (CGM), glycemic variability will be assessed using the coefficient of variation (%CV). Change in %CV will be calculated across time-points.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in Hemoglobin A1c (HbA1c)
HbA1c (%) reflects average glucose over the past 2-3 months. Value will be assessed by standardized laboratory assay for trial baseline and endpoint.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in Healthy Eating Index (HEI) Score based on two 24-hour recalls
Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Healthy Eating Index (HEI) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating from a select list of healthy food categories. The scores range from 0 to 100. An ideal overall Healthy Eating Index score of 100 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Change in Mediterranean diet scores
Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Mediterranean diet scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating a set amount of serving from a select list of healthy food categories. The scores range from 0 to 9. An ideal overall Mediterranean diet score of 9 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in Dietary Approaches to Stop Hypertension (DASH) Scores
Participants will be contacted to collect two 24-hour dietary recalls per timepoint. Dietary Approaches to Stop Hypertension (DASH) scores will be calculated based on the recall responses using a scoring system providing cumulative points for participants eating a set amount of serving from a select list of healthy food categories. The scores range from 8 to 40. An ideal overall DASH score of 40 reflects that the set of foods aligns with key dietary recommendations from the Dietary Guidelines for Americans (DGA).
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in food security using the USDA Food Security Survey Module
Self-reported United States Department of Agriculture (USDA) Household Food Security Survey will be measured using the 6-item short form with a 30-day lookback period. Responses of either "often", "sometimes", and "yes" on the questionnaire are added up to produce a total raw score, which will be used to measure changes across timepoints in the study. A total raw score of 0-1 indicates high or marginal food security, 2-4 indicates low food security, and 5-6 indicates very low food security.
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Change in the presence and/or degree of nutrition security from the Two-item Nutrition Security Screener (NSS)
Self-reported 2-item Nutrition Security Screener will be measured to assess the presence and/or degree of nutrition security with the following question: "Thinking about the last 12 months, how hard was it for you or your household to regularly get and eat healthy foods?" The scale yields a nutrition security score based on a 5-point Likert scale ranging from "Very Hard" to "Not hard at all". Responses of "Very Hard", "Hard", or "Somewhat Hard" yield the presence of nutrition insecurity.
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in the summed nutrition barrier score from the Two-item Nutrition Security Screener (NSS)
Self-reported 2-item Nutrition Security Screener will be measured to assess sum of reasons of nutrition barriers with the following question: "People have different reasons for eating or not eating healthy foods. Please tell me which, if any, of the following reasons were true for you or your household in the last 12 months." Participants will have 14 choices to choose from indicating their reason(s) for nutrition barriers, with each reason counting as a score of 1. There is no limit on the number of choices. Each reason checked off will be summed for a total score used to compare between the timepoints for changes in nutrition barrier score.
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in the One-Item Gretchen Swanson Nutrition Screener
Self-reported 1-item Gretchen Swanson Nutrition Screener will be measured to assess the participant's needs for support around accessing healthy foods by asking the following question: "In the last 12 months, I worried that the food I was able to eat would hurt my health and well-being." The scale yields a score based on the response rated on a 6-point Likert scale, ranging from Never, Rarely, Sometimes, Often, Always, and Don't know. Responses with "Sometimes", "Often", and "Always" yields a positive screen, indicating a need for support around accessing healthful foods. Responses with "Never", "Rarely", and "Don't know" yields a negative screen to indicate no need for support around accessing healthful foods.
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in Core Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score
Self-reported core diabetes distress will be measured using the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) Core Score. The scale yields a core score that is the average of all core questions (first 8 items) responses rated on a 5-point Likert scale for all 8 items (range 1-5), with higher scores indicating higher distress. A score \>= 2.0 is considered clinically significant diabetes distress.
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Change in Sources of Diabetes Distress using the Type 2 Diabetes Distress Assessment System (T2-DDAS) Source Scores
Self-reported sources of diabetes distress will be measured using the 7 source scales of the 29-item Type 2 Diabetes Distress Assessment System (T2-DDAS) source scale. In addition to the core score, the T2-DDAS scale also yields a score for each of 7 source scales based on the average response on all of the remaining items in the 29-item survey. The 7 source scale scores include: Management Demands, Hypoglycemia, Interpersonal issues, Healthcare provider, Shame/Stigma, Long-term Health, and Healthcare Access. Each of these is measured the same way, on the same 5-point Likert scale (range 1-5), with higher scores indicating higher distress. A score \>= 2.0 is considered clinically significant diabetes distress for each source.
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Changes in the Benefits of Continuous Glucose Monitor (BenCGM)
Self-reported BenCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items based on a Likert 5-point scale ranging from 1-5, with a choice of 1 being "Strongly Disagree" to a choice of 5 indicating "Strongly Agree." Changes will be calculated between timepoints
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Changes in the Burdens of Continuous Glucose Monitor (BurCGM)
Self-reported BurCGM 8-item survey will be measured. The scale yields a score based on the scale mean taken across all items based on a Likert 5-point scale ranging from 1-5, with a choice of 1 being "Strongly Disagree" to a choice of 5 indicating "Strongly Agree.". Changes will be calculated between timepoints.
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Changes in the 10-item Dietary Screener Questionnaire (DSQ) with a lookback of 30 days.
The 10-item Dietary Screener Questionnaire (DSQ) is a validated instrument used to self-report fruit and vegetables intake across different various types of foods. Responses to each question will be sorted either as a fruit, vegetable, or both to generate a score based on intake frequency per month, with choices ranging from "Never" to "6 or more times a day" Results will be calculated by converting the response to cup equivalent estimates of average daily dietary intake and compared across study timepoints.
Time frame: Baseline at Week 0, Post-Intervention at Week 12, Post-extension at Week 16
Change in Physical Activity Levels
A self-reported Previous Day Physical Activity Recall (PDPAR) will be administered in interview calls measuring frequency of activity from the prior day at the time of the call. Information regarding activity type and intensity levels (ranging light, moderate, hard, and very hard) will be asked for every hour of the wake spent awake. Intensity levels will be used to calculate metabolic equivalent task (MET) values corresponding to each level of intensity to evaluate energy expenditure. MET values will be compared against different timepoints of the study and between study arms.
Time frame: Baseline at Week 0, Post-intervention at Week 12, Post-extension at Week 16
Change in Food Assistance enrollment (SNAP / WIC) in the last 30 days.
Participants will self-report the following question: "Have you received federal food assistance through either SNAP or WIC in the past 30 days." Changes in response of either yes or no will be compared between timepoints.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Changes in financial strain, from the American Academy of Family Physicians (AAFP) Social Needs Screening Tool
Participants will self-report the following question from the American Academy of Family Physicians (AAFP) Social Needs Screening Tool: "How often does this describe you? I don't have money to pay my bills (including food, housing, medical care or heating). Never / Rarely / Sometimes / Often / Always" Responses of "Sometimes", "Often", and "Always" yield a positive screen, with a response of "Never" and "Rarely" yielding a negative screen. Scores will be compared between timepoints.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in General Health Status
Participants will self-report the following question from the General Health Status: "Would you say that in general your health is excellent, very good, good, fair, or poor?" Response will be compared between timepoints.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in EuroQol 5 Dimension, 5 Level (EQ-5D-5L)
The EuroQol 5 Dimension, 5 Level (EQ-5D-5L) is a self-reported questionnaire that measures general health status in the realms of mobility, self-care, usual activities, pain discomfort, and anxiety/depression. Responses to the 5 questions are based on a Likert 5-point scale measuring severity of problem, with 1 indicating no problems and 5 indicating severe problems. Responses for each question will be concatenated to a 5-digit state in order of mobility, self-care, usual activities, pain discomfort, and anxiety/depression, and then converted to an index score between 0-1. A higher score indicates greater quality of life. Index scores will be compared between timepoints .
Time frame: Baseline at Week 0, Post-intervention at Week 12
Change in overall health status in the EuroQol 5 Dimensions, 5 Level (EQ-5D-5L)
The EuroQol 5 Dimension, 5 Level (EQ-5D-5L) is a self-reported questionnaire that measures general health status in the realms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the end of the questionnaire, there is a visual analog scale measuring overall health status with the prompt: "We would like to know how good or bad your health is TODAY". Participants will slide the scale to indicate a number ranging from 0 being "The worst health you can imagine" to 100 being "The best health you can imagine". Responses to this question will be compared between timepoints.
Time frame: Baseline at Week 0, Post-intervention at Week 12
Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 6 to 18 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Time frame: beginning 6 and continuing for 18 months following publication
Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 15 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →